Technical Analysis for GILD - Gilead Sciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
74.03 | -1.50% | -1.13 |
GILD closed down 3.43 percent on Monday, June 1, 2020, on 73 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Jun 19
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical GILD trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | -1.50% | |
| Fell Below 50 DMA | Bearish | -1.50% | |
| Cup with Handle | Other | -1.50% | |
| Crossed Above 20 DMA | Bullish | -4.88% | |
| Crossed Above 50 DMA | Bullish | -4.88% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -4.88% | |
| Pocket Pivot | Bullish Swing Setup | -4.88% | |
| Outside Day | Range Expansion | -4.88% | |
| Up 3 Days in a Row | Strength | -4.88% | |
| Shooting Star Candlestick | Bearish | -1.71% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/19/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Coronavirus Organic Chemistry Cystic Fibrosis Pulmonary Arterial Hypertension Cardiovascular Diseases HIV Hepatotoxins Respiratory Diseases Gilead Sciences Liver Disease Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections Tenofovir Disoproxil
Medicine Chemistry Biopharmaceutical Diseases Infection Coronavirus Organic Chemistry Cystic Fibrosis Pulmonary Arterial Hypertension Cardiovascular Diseases HIV Hepatotoxins Respiratory Diseases Gilead Sciences Liver Disease Prodrugs AIDS Cytomegalovirus Retinitis Fungal Infections Tenofovir Disoproxil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 85.97 |
| 52 Week Low | 60.89 |
| Average Volume | 20,185,251 |
| 200-Day Moving Average | 68.81 |
| 50-Day Moving Average | 76.66 |
| 20-Day Moving Average | 76.27 |
| 10-Day Moving Average | 74.42 |
| Average True Range | 2.73 |
| ADX | 10.37 |
| +DI | 21.68 |
| -DI | 17.74 |
| Chandelier Exit (Long, 3 ATRs ) | 77.48 |
| Chandelier Exit (Short, 3 ATRs ) | 80.49 |
| Upper Bollinger Band | 80.94 |
| Lower Bollinger Band | 71.59 |
| Percent B (%b) | 0.38 |
| BandWidth | 12.26 |
| MACD Line | -0.69 |
| MACD Signal Line | -0.67 |
| MACD Histogram | -0.0162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 78.94 | ||||
| Resistance 3 (R3) | 79.10 | 78.00 | 78.31 | ||
| Resistance 2 (R2) | 78.00 | 77.04 | 77.92 | 78.10 | |
| Resistance 1 (R1) | 76.58 | 76.44 | 76.03 | 76.42 | 77.89 |
| Pivot Point | 75.48 | 75.48 | 75.21 | 75.40 | 75.48 |
| Support 1 (S1) | 74.06 | 74.52 | 73.51 | 73.90 | 72.43 |
| Support 2 (S2) | 72.96 | 73.92 | 72.88 | 72.22 | |
| Support 3 (S3) | 71.54 | 72.96 | 72.01 | ||
| Support 4 (S4) | 71.38 |
